Thyroid News and Research RSS Feed - Thyroid News and Research

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Young thyroid cancer patients with lymph node involvement at increased risk of dying

Young thyroid cancer patients with lymph node involvement at increased risk of dying

Patients older than age 45 with thyroid cancer that has spread to neck lymph nodes have long been considered at higher risk of dying, but the same has not been true for younger patients. [More]
Breakthrough discovery on element transformation could lead to new way for treating cancer with radiation

Breakthrough discovery on element transformation could lead to new way for treating cancer with radiation

Chemists at Tufts University's School of Arts and Sciences, collaborating with PerkinElmer and UCL (University College London), have witnessed atoms of one chemical element morph into another for the first time ever -- a feat that produced an unexpected outcome that could lead to a new way to safely treat cancer with radiation. [More]
Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

In preliminary experiments with mice and lab-grown cells, Johns Hopkins Kimmel Cancer Center scientists have found that a protein-signaling process accelerates the work of the gene most frequently mutated in a common form of adult leukemia and is likely necessary to bring about the full-blown disease. [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
New article published in Spanish Journal of Pathology highlights a rare case of Hodgkin's lymphoma

New article published in Spanish Journal of Pathology highlights a rare case of Hodgkin's lymphoma

Dr. Jerónimo Forteza, Professor of Pathology and Director of the Valencian Institute of Pathology, Catholic University of Valencia "San Vicente Mártir," recently published an article in the Spanish Journal of Pathology on the case of a patient with Hodgkin's lymphoma. Medicine student Pablo Sánchez Vela performed this diagnostic work under the supervision of Dr. Forteza. [More]
University of Bonn researchers find way to stimulate larynx muscles using light

University of Bonn researchers find way to stimulate larynx muscles using light

Researchers at the University of Bonn have found a way to stimulate the larynx muscles of mice using light. In the long term, this method could be an option for the treatment of laryngeal paralysis, which causes difficulties in phonation and breathing. Their findings will be published in the scientific journal "Nature Communications." [More]
Innovative mini hybrid gamma ray camera improves removal of tumours and lymph nodes

Innovative mini hybrid gamma ray camera improves removal of tumours and lymph nodes

Universities of Leicester and Nottingham to develop mini hybrid gamma ray camera to revolutionise identification and removal of tumours and lymph nodes [More]
Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone. [More]
Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]
Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2. [More]
Patient characteristics may guide TKI use in CML

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests. [More]
New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. [More]
Subclinical hyperthyroidism linked to increased fracture risk

Subclinical hyperthyroidism linked to increased fracture risk

In an analysis that included more than 70,000 participants from 13 studies, subclinical hyperthyroidism was associated with an increased risk for hip and other fractures including spine, according to a study in the May 26 issue of JAMA. Subclinical hyperthyroidism is a low serum thyroid-stimulating hormone concentration in a person without clinical symptoms and normal thyroid hormone concentrations on blood tests. [More]
Study evaluates VolitionRx's proprietary Nucleosomics platform in most prevalent cancers

Study evaluates VolitionRx's proprietary Nucleosomics platform in most prevalent cancers

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has accelerated its large independent prospective study evaluating its proprietary Nucleosomics platform at University Hospital Bonn in Germany. [More]
Misperceptions about miscarriage are widespread, survey finds

Misperceptions about miscarriage are widespread, survey finds

A survey of more than 1,000 U.S. adults has found that misperceptions about miscarriage and its causes are widespread. Results of the survey, conducted by researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Health System, show that feelings of guilt and shame are common after a miscarriage and that most people erroneously believe that miscarriages are rare. [More]
GTEx findings reveal how genomic variants can affect gene activity and disease susceptibility

GTEx findings reveal how genomic variants can affect gene activity and disease susceptibility

Researchers funded by the National Institutes of Health Genotype-Tissue Expression (GTEx) project have created a new and much-anticipated data resource to help establish how differences in an individual's genomic make-up can affect gene activity and contribute to disease. [More]
Paediatric primary hyperparathyroidism in rarely a familial disorder

Paediatric primary hyperparathyroidism in rarely a familial disorder

Researchers report that primary hyperparathyroidism in children and adolescents is usually caused by a sporadic single parathyroid adenoma. [More]
Thyroid ultrasound ‘not highly accurate’ for malignancy in children

Thyroid ultrasound ‘not highly accurate’ for malignancy in children

Ultrasound has only limited value for diagnosing thyroid cancer in children, say the authors of a meta-analysis. [More]
OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

The Ontario Health Technology Advisory Committee has recommended Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU or MRgFUS) as a possible "cost-effective strategy" and a "safe and effective, noninvasive, uterine-preserving" option for women seeking treatment for uterine fibroids. [More]
Advertisement
Advertisement